ART 5803
Alternative Names: ART-5803Latest Information Update: 01 Oct 2025
At a glance
- Originator Arialys Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Yes - Anti-N-methyl-D-aspartate receptor encephalitis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anti-N-methyl-D-aspartate receptor encephalitis
Most Recent Events
- 25 Sep 2025 US FDA grants Rare Pediatric Disease Designation to ART 5803 for Anti-N-methyl-D-aspartate receptor encephalitis in USA
- 11 Sep 2025 Arialys Therapeutics completes a phase I trial for anti N-methyl-D-aspartate receptor encephalitis (In volunteers) in Australia (IV, Infusion) (NCT06575153)
- 18 Jun 2025 Pharmacodynamics data from a preclinical studies in Anti-N-methyl-D-aspartate receptor encephalitis released by Arialys Therapeutics